Neurology

A treatment for multiple sclerosis that treats the most common form of the disease may help reverse some physical disabilities.

After keeping her multiple sclerosis diagnosis a secret for more than a decade, Jamie-Lynn Sigler, teamed up with Biogen’s MS campaign.

Sudden sensorineural hearing loss occurs more often in patients with multiple sclerosis than among the general population.

Researchers unveil the molecular workings of MS drug Tecfidera using new technology.

With no current treatments for patients with aggressive MS, new study findings provide hope.

Laquinimod provides hope for inhibiting aggressive multiple sclerosis.

A nanoparticle delivery system may help manage autoimmune diseases, such as multiple sclerosis, leaving a temporary black mark on patients.

Gilenya (fingolimod) can slow disability progression in patients with relapsing remitting multiple sclerosis.

A new biomarker reveals how the disease will progress in patients.

Research improves projection of multiple sclerosis disease progression.

Laquinimod showed superior results in one trial over another in multiple sclerosis patients.

Methods of trail that examined laquinimod for relapsing-remitting multiple sclerosis scrutinized by researchers.

Improved understanding of disease modifying drugs can help patients with MS achieve better outcomes.

Confidence intervals can improve adherence to disease modifying drugs in the care of multiple sclerosis.

New findings may lead to new therapies for multiple sclerosis.

This Continuing Education activity is supported by educational grants from Sanofi-Aventis US Genzyme and Novartis Pharmaceuticals Corporation.

Ozanimod met all primary and secondary endpoints of the RADIANCE trial in patients with relapsing multiple sclerosis.

Ocrevus (ocrelizumab) effective in patients with relapsing and primary progressive multiple sclerosis.

Ocrelizumab (Ocrevus) may improve treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.

Nutra Pharma and Omnia Biologics will partner to create pediatric multiple sclerosis treatment derived from cobra venom.

People of color who are underrepresented in multiple sclerosis clinical trials need to be engaged.

The FDA has approved 14 disease-modifying medications for use in relapsing forms of multiple sclerosis.

Biogen will discuss results from various studies examining their expansive portfolio of multiple sclerosis drugs.

Novartis experimental drug BAF312 met its primary endpoints in a phase 3 study.

The heavy reliance on MRI abnormalities and the tendency of multiple sclerosis to resemble other rare diseases leads to misdiagnoses.